Sartorius Stedim Biotech (DIM) Stock Chart & Stock Price History €177.85 +1.55 (+0.88%) As of 08/22/2025 Add Compare Share Share Chart Stock AnalysisChartHeadlinesBuy This Stock Sartorius Stedim Biotech Stock Price Performance The Sartorius Stedim Biotech (DIM) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has increased 1.40%, with a year-to-date return of -3.47%. In the past month, the stock has increased 2.89%, reflecting recent market activity. As of the latest close, Sartorius Stedim Biotech traded at €176.30 with a market cap of and volume of 45,113 shares. Five years ago, the stock traded at €296.60, representing a 40.04% decrease over that period. At the time, it had a market cap of and a volume of 40,006 shares. Receive DIM Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Sartorius Stedim Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+0.20%1 Month Performance+2.89%3 Month Performance-9.07%Year-To-Date Performance-3.47%1 Year Performance+1.40%5 Year Performance-40.04% DIM Stock Chart for Sunday, August, 24, 2025 DIM Chart by TradingView Sartorius Stedim Biotech Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/22/2025€179.40€176.30-1.73%€180.65€176.1545,113 shs$0.0008/21/2025€179.30€179.40+0.06%€180.35€178.0032,566 shs$0.0008/20/2025€177.50€179.30+1.01%€179.60€175.8057,490 shs$0.0008/19/2025€177.40€177.50+0.06%€178.00€175.5064,971 shs$0.0008/18/2025€177.40€177.40€178.75€176.7549,168 shs$0.0008/15/2025€176.00€177.00+0.57%€179.20€175.2052,871 shs$0.0008/14/2025€177.10€176.00-0.62%€179.00€175.2073,061 shs$0.0008/13/2025€169.30€177.10+4.61%€178.10€169.8080,423 shs$0.0008/12/2025€166.85€169.30+1.47%€169.30€167.9040,334 shs$0.0008/11/2025€166.85€166.85€168.60€166.0056,789 shs$0.00 Get the Latest News and Ratings for DIM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Sartorius Stedim Biotech and its competitors with MarketBeat's FREE daily newsletter. 08/08/2025€165.55€167.60+1.24%€168.15€164.4066,261 shs$0.0008/07/2025€169.90€165.55-2.56%€170.15€165.5568,692 shs$0.0008/06/2025€169.90€169.90€171.50€167.9551,688 shs$0.0008/05/2025€171.65€169.90-1.02%€171.50€167.9551,688 shs$0.0008/04/2025€171.65€171.65€173.85€170.3574,413 shs$0.0008/01/2025€177.90€176.00-1.07%€179.80€175.8586,585 shs$0.0007/31/2025€179.55€177.90-0.92%€181.90€177.9055,539 shs$0.0007/30/2025€175.90€179.55+2.08%€181.15€176.3076,290 shs$0.0007/29/2025€175.00€175.90+0.51%€180.35€175.9093,089 shs$0.0007/28/2025€175.00€175.00€176.70€172.6071,463 shs$0.0007/25/2025€172.85€175.25+1.39%€177.00€172.0568,004 shs$0.0007/24/2025€175.00€172.85-1.23%€180.00€172.85144,287 shs$0.0007/23/2025€190.45€175.00-8.11%€192.00€166.70407,974 shs$0.00 Related Companies Fielmann Group Stock Price Chart Sartorius Aktiengesellschaft Stock Price Chart Sartorius Aktiengesellschaft Stock Price Chart Carl Zeiss Meditec Stock Price Chart Gerresheimer Stock Price Chart Fresenius SE & Co. KGaA Stock Price Chart Genfit Stock Price Chart Sanofi Stock Price Chart Siemens Healthineers Stock Price Chart Merck KGaA Stock Price Chart Receive DIM Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Sartorius Stedim Biotech and its competitors with MarketBeat's FREE daily newsletter. This page (EPA:DIM) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sartorius Stedim Biotech S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sartorius Stedim Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access